ADC precision therapy could prevent breast cancer, study shows
New research has identified a precision therapy which could stop breast cancer at the source.
Researchers at the University of California San Diego School of Medicine used an antibody-drug conjugate (ADC) to target a cell-surface protein known as FZD7. FZD7 is present on cells with high tumour-initiating potential in triple-negative breast cancer but, by using the ADC to target FZD7, scientists significantly reduced tumour growth in mouse models.
Triple-negative breast cancer is among the most aggressive and difficult-to-treat forms of cancer. Data from the University of California estimates that, by the end of 2025, 316,950 women and 2,800 men will have been diagnosed with breast cancer.
Triple-negative breast cancer is particularly dangerous because it tends to grow and spread faster than other types of breast cancer. It typically fails to respond to treatments that work in other forms of cancer, such as hormonal therapies, and survival rates for patients with triple-negative breast cancer remain low.
The research, published in Proceedings of the National Academy of Sciences, offers hope that ADCs targeting FZD7 could provide new ways to treat triple-negative breast cancer. The approach was effective in human cell lines but further research is needed to advance the treatment to clinic.
Bruno Quinney, Content Team, DDW
